Shots:
- Organogenesis has reported the trial completion of PuraPly AM, assessing it in combination with SoC vs SOC alone for the management of non-healing diabetic foot ulcers (DFUs)
- The 170-patient trial achieved its 1EP, showing significant wound closure at 12wks., with the company planning to publish the study results soon in a journal
- PuraPly AM combines a native, cross-linked collagen matrix with polyhexamethylene biguanide antimicrobial to manage bioburden & support wound healing
Ref: Globenewswire | Image: Organogenesis|Press Release
Related News: Zeto Receives US FDA 510(k) Clearance for Zeto New Wave to Advance Outpatient EEG
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
